Imatinib (Gleevec) — CML Targeted Therapy

Imatinib (brand name Gleevec/Glivec) revolutionised the treatment of Chronic Myeloid Leukaemia (CML) by specifically targeting the BCR-ABL fusion protein driving disease. Before Imatinib, CML required bone marrow transplantation; now, most CML patients achieve deep molecular remission on oral targeted therapy and live normal lives. At our centre, Dr. Joshi manages CML with Imatinib and newer generation TKIs (Dasatinib, Nilotinib, Ponatinib) based on Sokal/EUTOS risk scores and treatment response monitoring by BCR-ABL PCR. Imatinib is also used in CD117-positive Gastrointestinal Stromal Tumours (GISTs). Regular monitoring and mutation testing ensure optimal long-term disease control.

📋 Treatment Overview

📅 Schedule a Consultation

Talk to Dr. Joshi about whether this treatment is right for you. OPD: Mon–Thu, 10 AM – 1 PM.